Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter ...
The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
Please provide your email address to receive an email when new articles are posted on . The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment ...
"The FDA's Breakthrough Device Designation for our CRISPR-TB Blood Test is a significant milestone for IntelliGenome. This recognition highlights our commitment to advancing innovative, accessible ...
Rezolute, Inc. announced that the FDA has granted Breakthrough Therapy Designation to its drug, ersodetug, for treating hypoglycemia caused by congenital hyperinsulinism. This designation ...
Now, with its latest achievements, CergenX plans to collaborate with the FDA throughout the Wave device’s development and premarket review. “Receiving the Breakthrough Device Designation and ...
A CergenX-led consortium, including UCC/ INFANT, was awarded €6.7 million in funding from The Disruptive Technologies ...
These forward-looking statements include but are not limited to statements regarding the FDA’s grant of the Breakthrough Therapy Designation for ersodetug, the ersodetug Expanded Access Program ...
Breakthrough Therapy Designation is generally granted to ... This designation will provide Denali with more intensive FDA guidance, including involvement of senior reviewers, and eligibility ...